---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-139169"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2021-11-15T23:59:59+00:00"
generated_at: "2026-06-28T08:27:18.936938+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NextCure reports NC318 37% DCR, 5.0 mo median PFS; NC410 safe in Ph1

## Summary
- NC318 Phase 1/2: 37% disease control rate, median PFS 5.0 mo across all tumors; lung cohort 45% DCR, median PFS 5.2 mo.
- Two NSCLC patients on NC318 >2 years: one CR at 2.8 years, one PR at 2.2 years.
- Modeling predicts 800 mg weekly NC318 yields ~10x exposure; sS15 may be biomarker for patient selection.
- NC410 Ph1 (n=19) up to 60 mg Q2W: no dose-limiting toxicities; shows target binding, immune modulation, ECM remodeling.
- Non-clinical data: NC410 synergizes with bintrafusp alpha (TGF-β trap) for tumor control in colon cancer model.

## SEC filing metadata
- accession: 0001104659-21-139169
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2021-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465921139169/0001104659-21-139169-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465921139169/tm2132890d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-139169
- JSON: https://secwatch.observer/filing/0001104659-21-139169.json
- Plain text: https://secwatch.observer/filing/0001104659-21-139169.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.